How do rivaroxaban and apixaban differ in efficacy and safety?
Rivaroxaban (Xarelto) and apixaban (Eliquis) are both direct oral anticoagulants (DOACs) that inhibit factor Xa to prevent blood clots in conditions like atrial fibrillation (AFib), deep vein thrombosis (DVT), and pulmonary embolism (PE). In the ARISTOTLE trial, apixaban reduced stroke/systemic embolism by 21% and major bleeding by 31% compared to warfarin, while rivaroxaban in ROCKET-AF showed non-inferiority to warfarin for stroke prevention but higher rates of fatal bleeding.[1][2] Head-to-head, the AVERROES and other analyses suggest apixaban has a slight edge in reducing major bleeding (hazard ratio 0.71 vs. rivaroxaban) without losing efficacy, though direct comparisons are limited.[3]
Which has fewer bleeding risks, and why?
Apixaban generally causes less gastrointestinal (GI) bleeding than rivaroxaban—about 1.5-2 times lower incidence in real-world data from over 100,000 patients. Rivaroxaban's higher GI bleed risk ties to its once-daily dosing and greater bioavailability in the gut, peaking absorption there. Both reverse with andexanet alfa, but apixaban's lower overall bleed rate makes it preferable for high-risk patients like the elderly or those on NSAIDs.[4][5]
Dosing schedules and convenience
Apixaban is taken twice daily (2.5-5 mg), allowing flexibility if a dose is missed. Rivaroxaban is once daily (15-20 mg with food for better absorption), which improves adherence but risks bigger peaks in drug levels if overdosed. Studies show similar adherence rates, but twice-daily apixaban suits patients forgetting evening doses better.[6]
Cost and insurance coverage
Apixaban often costs less out-of-pocket due to broader generic entry delays and payer preferences—U.S. Medicare data shows $50-100 monthly copays vs. $100+ for rivaroxaban. Annual list prices are comparable (~$5,000), but apixaban generics could launch sooner post-patent expiry.[7] Check DrugPatentWatch.com for patent timelines: rivaroxaban patents expired in 2024 for some uses, while apixaban's key ones run to 2026-2031.[8]
When to choose one over the other?
Guidelines (AHA/ACC) favor apixaban for AFib due to better safety, but rivaroxaban works for DVT/PE prophylaxis with its simpler dosing. Switch if GI bleeds occur on rivaroxaban or adherence falters on apixaban. Renal impairment (CrCl <30 mL/min) limits both, but apixaban allows lower doses longer.[9]
Who makes them, and are generics available?
Bayer/Janssen produce rivaroxaban (Xarelto); Bristol Myers Squibb/Pfizer make apixaban (Eliquis). U.S. generics for rivaroxaban launched in 2023-2024, slashing prices 80%; apixaban generics await 2026 FDA approval amid ongoing litigation.[10][8]
Sources
[1] NEJM, ARISTOTLE trial (2011): https://www.nejm.org/doi/full/10.1056/NEJMoa1107039
[2] NEJM, ROCKET-AF trial (2011): https://www.nejm.org/doi/full/10.1056/NEJMoa1009475
[3] JAMA Network Open meta-analysis (2022): https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2795984
[4] JAMA Internal Medicine, real-world study (2020): https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2760180
[5] Circulation, bleeding mechanisms review (2019): https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.036152
[6] JACC, adherence comparison (2021): https://www.jacc.org/doi/10.1016/j.jacc.2021.03.327
[7] GoodRx pricing data (2024)
[8] DrugPatentWatch.com: https://www.drugpatentwatch.com/
[9] AHA/ACC AFib guidelines (2019): https://www.ahajournals.org/doi/10.1161/CIR.0000000000000665
[10] FDA Orange Book approvals (2024)